兰地洛尔用于治疗心律失常:一篇最先进的评论
Muhammad Ghallab1, Mahmoud Samy Ahmed2, Talia H Ostrow3
1From the Department of Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY.
Cardiology in review
|March 13, 2024
概括
兰地醇是一种心脏选择性β-阻断剂,由于其短半衰期和血压影响最小,它对治疗各种心律失常有前途. 需要进一步的研究来优化其使用,并探索其更广泛的治疗潜力.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
背景情况:
- 兰迪洛尔是一种新型的超短效β阻断剂.
- 它表现出高的心脏选择性和短半衰期.
- 其独特的特性使其与传统的β-阻断剂有所区别.
研究的目的:
- 审查兰地的药理学,药理动力学和药理动力学.
- 为了将兰迪奥洛尔与传统的β-阻断剂比较,例如esmolol.
- 探索兰地洛尔在心律失常管理及其他领域当前和潜在的临床应用.
主要方法:
- 对兰迪奥洛尔的特性和临床研究的文献综述.
- 对药理学,药理动力学和药理动力学的分析.
- 检查预防手术后心房动和管理动脉节律失常症的疗效.
主要成果:
- 兰地醇具有高心脏选择性,半衰期短,对血压的影响最小.
- 临床试验表明,在预防术后心房动方面具有有效性.
- 潜在的应用包括控制心房/鼓动率和管理与败血症相关的动脉节律不良.
结论:
- 兰地洛尔为心律失常治疗提供了一个有希望的替代方案,特别是在特定的临床场景中.
- 它的潜力扩展到抗炎,抗氧化,止痛和抗癌作用.
- 需要进一步的研究来优化剂量,确定患者群体,并了解其机制.
相关概念视频
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
992
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
992
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
743
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
743
Adrenergic Antagonists: ɑ and β-Receptor Blockers
446
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
446
Heart Failure Drugs: Inotropic Agents
584
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
584


